Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus DOI
Carolyn F. Deacon

Nature Reviews Endocrinology, Journal Year: 2020, Volume and Issue: 16(11), P. 642 - 653

Published: Sept. 14, 2020

Language: Английский

American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity DOI Open Access
W. Timothy Garvey,

Jeffrey I. Mechanick,

Elise M. Brett

et al.

Endocrine Practice, Journal Year: 2016, Volume and Issue: 22, P. 1 - 203

Published: May 24, 2016

Language: Английский

Citations

1393

American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease DOI Open Access

Paul S. Jellinger,

Yehuda Handelsman,

Paul D. Rosenblit

et al.

Endocrine Practice, Journal Year: 2017, Volume and Issue: 23, P. 1 - 87

Published: April 1, 2017

Language: Английский

Citations

986

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association DOI Open Access
Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson

et al.

Diabetes Care, Journal Year: 2015, Volume and Issue: 38(10), P. 1964 - 1974

Published: Sept. 15, 2015

Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum progresses sequentially variable but predictable rates through distinct identifiable stages prior to onset symptoms. Stage defined as presence β-cell autoimmunity evidenced by two or more islet autoantibodies with normoglycemia and presymptomatic, stage 2 dysglycemia 3 symptomatic disease. Adoption this staging classification provides standardized taxonomy will aid development therapies design clinical trials prevent disease, promote precision medicine, provide framework an optimized benefit/risk ratio impact regulatory approval, reimbursement, adoption interventions in early

Language: Английский

Citations

917

Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY DOI Open Access

Alan J. Garber,

Martin J. Abrahamson, Joshua I. Barzilay

et al.

Endocrine Practice, Journal Year: 2016, Volume and Issue: 22(1), P. 84 - 113

Published: Jan. 1, 2016

Language: Английский

Citations

692

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors DOI Creative Commons
William H. Polonsky, Robert R. Henry

Patient Preference and Adherence, Journal Year: 2016, Volume and Issue: Volume 10, P. 1299 - 1307

Published: July 1, 2016

Poor medication adherence in type 2 diabetes: recognizing the scope of problem and its key contributors William H Polonsky,1,2 Robert R Henry2,3 1Behavioral Diabetes Institute, San Diego, 2University California, 3Center for Metabolic Research, VA Diego Healthcare System, San Diego, CA, USA Abstract: At least 45% patients with diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One major contributing factors is poor adherence. T2D well documented be very common associated inadequate control; increased morbidity mortality; costs outpatient care, emergency room visits, hospitalization, managing complications diabetes. linked nonpatient (eg, lack integrated care many health systems clinical inertia among professionals), patient demographic young age, low education level, income level), critical beliefs about their medications perceived treatment inefficacy), burden regarding obtaining taking complexity, out-of-pocket costs, hypoglycemia). Specific barriers T2D, especially those that are potentially modifiable, need more clearly identified; strategies target should focus on reducing addressing negative patients. Solutions these problems would require behavioral innovations as new methods modes drug delivery. Keywords: control, HbA1c, hypoglycemia, adherence, psychosocial,

Language: Английский

Citations

603

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial DOI
Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2018, Volume and Issue: 6(4), P. 275 - 286

Published: Feb. 1, 2018

Language: Английский

Citations

584

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary DOI Open Access

Alan J. Garber,

Yehuda Handelsman, George Grunberger

et al.

Endocrine Practice, Journal Year: 2020, Volume and Issue: 26(1), P. 107 - 139

Published: Jan. 1, 2020

Language: Английский

Citations

548

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary DOI Open Access

Alan J. Garber,

Martin J. Abrahamson, Joshua I. Barzilay

et al.

Endocrine Practice, Journal Year: 2018, Volume and Issue: 24(1), P. 91 - 121

Published: Jan. 1, 2018

Language: Английский

Citations

491

Bariatric surgery for obesity and metabolic disorders: state of the art DOI
Ninh T. Nguyen, J. Esteban Varela

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2016, Volume and Issue: 14(3), P. 160 - 169

Published: Nov. 30, 2016

Language: Английский

Citations

441

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary DOI Open Access

Alan J. Garber,

Martin J. Abrahamson, Joshua I. Barzilay

et al.

Endocrine Practice, Journal Year: 2017, Volume and Issue: 23(2), P. 207 - 238

Published: Jan. 17, 2017

Language: Английский

Citations

422